Bharat Biotech’s Covaxin gets WHO approval for Emergency Use Listing

November 3

Bharat Biotech’s Covaxin gets WHO approval

Bharat Biotech’s Covaxin gets World Health Organisation (WHO) approval for Emergency Use Listing.

The global health group’s Technical Advisory Group (TAG) issued the final decision.

The WHO, in a tweet, said: “WHO has granted emergency use listing (EUL) to Covaxin, developed by Bharat Biotech, adding to a growing portfolio of vaccines validated by WHO for the prevention of Covid 19”.

Covaxin was co-developed by Hyderabad-based Bharat Biotech, in collaboration with the government’s Indian Council of Medical Research (ICMR).

It has demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the new Delta variant.

WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson 7 Johnson – Janssen, Moderna, and Sinopharm for emergency use against Covid-19.

The approval is important because it removes uncertainty around overseas travel by Indian inoculated with Covaxin